Related references
Note: Only part of the references are listed.Assessment and Reporting of the Clinical Immunogenicity of Therapeutic Proteins and Peptides-Harmonized Terminology and Tactical Recommendations
G. Shankar et al.
AAPS JOURNAL (2014)
Measurement of in Vivo Drug Load Distribution of Cysteine-Linked Antibody-Drug Conjugates Using Microscale Liquid Chromatography Mass Spectrometry
Shawna Mae Hengel et al.
ANALYTICAL CHEMISTRY (2014)
Assessment of Physical Stability of an Antibody Drug Conjugate by Higher Order Structure Analysis: Impact of Thiol- Maleimide Chemistry
Jianxin Guo et al.
PHARMACEUTICAL RESEARCH (2014)
Antibody-Drug Conjugates in Cancer Therapy
Eric L. Sievers et al.
ANNUAL REVIEW OF MEDICINE, VOL 64 (2013)
Phase 1, open-label study of MEDI-547 in patients with relapsed or refractory solid tumors
Christina M. Annunziata et al.
INVESTIGATIONAL NEW DRUGS (2013)
Safety and Clinical Activity of a Combination Therapy Comprising Two Antibody-Based Targeting Agents for the Treatment of Non-Hodgkin Lymphoma: Results of a Phase I/II Study Evaluating the Immunoconjugate Inotuzumab Ozogamicin With Rituximab
Luis Fayad et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Key bioanalytical measurements for antibody-drug conjugate development: PK/PD modelers' perspective
Dhaval K. Shah et al.
BIOANALYSIS (2013)
Insights into antibody-drug conjugates: bioanalysis and biomeasures in discovery
Tracey Clark et al.
BIOANALYSIS (2013)
Immunogenicity assays for antibody-drug conjugates: case study with ado-trastuzumab emtansine
Montserrat Carrasco-Triguero et al.
BIOANALYSIS (2013)
Characterization of critical reagents in ligand-binding assays: enabling robust bioanalytical methods and lifecycle management
Brian J. Geist et al.
BIOANALYSIS (2013)
Bioanalysis of antibody-drug conjugates: American Association of Pharmaceutical Scientists Antibody-Drug Conjugate Working Group position paper
Boris Gorovits et al.
BIOANALYSIS (2013)
Immunogenicity testing strategy and bioanalytical assays for antibody-drug conjugates
Sarah A. Hoofring et al.
BIOANALYSIS (2013)
Bioanalytical assay strategies for the development of antibody-drug conjugate biotherapeutics
Surinder Kaur et al.
BIOANALYSIS (2013)
Ligand Binding Assays in the 21st Century Laboratory: Recommendations for Characterization and Supply of Critical Reagents
Denise M. O'Hara et al.
AAPS JOURNAL (2012)
Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody-drug conjugate in development for the treatment of HER2-positive cancer
Sandhya Girish et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2012)
Phase I studies of AVE9633, an anti-CD33 antibody-maytansinoid conjugate, in adult patients with relapsed/refractory acute myeloid leukemia
Simona Lapusan et al.
INVESTIGATIONAL NEW DRUGS (2012)
Phase I Multidose-Escalation Study of the Anti-CD19 Maytansinoid Immunoconjugate SAR3419 Administered by Intravenous Infusion Every 3 Weeks to Patients With Relapsed/Refractory B-Cell Lymphoma
Anas Younes et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Targeting the Hemoglobin Scavenger receptor CD163 in Macrophages Highly Increases the Anti-inflammatory Potency of Dexamethasone
Jonas H. Graversen et al.
MOLECULAR THERAPY (2012)
Pharmacokinetic Considerations for Antibody Drug Conjugates
Kedan Lin et al.
PHARMACEUTICAL RESEARCH (2012)
Identification and elimination of an immunodominant T-cell epitope in recombinant immunotoxins based on Pseudomonas exotoxin A
Ronit Mazor et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Tunable Degradation of Maleimide-Thiol Adducts in Reducing Environments
Aaron D. Baldwin et al.
BIOCONJUGATE CHEMISTRY (2011)
Analytical methods for physicochemical characterization of antibody drug conjugates
Aditya Wakankar et al.
MABS (2011)
Loss of CD4 T-cell-dependent tolerance to proteins with modified amino acids
Varun Gauba et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
Physicochemical Stability of the Antibody-Drug Conjugate Trastuzumab-DM1: Changes due to Modification and Conjugation Processes
Aditya A. Wakankar et al.
BIOCONJUGATE CHEMISTRY (2010)
The effect of antibody isotype and antigenic epitope density on the complement-fixing activity of immune complexes: a systematic study using chimaeric anti-NIP antibodies with human Fc regions
Y. M. LUCISANO VALIM et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2010)
A systematic study of neutrophil degranulation and respiratory burst in vitro by defined immune complexes
W. ZHANG et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2010)
The Pharmacologic Basis for Antibody-Auristatin Conjugate Activity
Stephen C. Alley et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2009)
Immunostimulatory activity of haptenated proteins
Noah W. Palm et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Contribution of linker stability to the activities of anticancer immunoconjugates
Stephen C. Alley et al.
BIOCONJUGATE CHEMISTRY (2008)
Cantuzumab mertansine in a three-times a week schedule: a phase I and pharmacokinetic study
Jordi Rodon et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2008)
Antibody-drug conjugates for cancer therapy
Paul J. Carter et al.
CANCER JOURNAL (2008)
Phase I trial of the prostate-specific membrane antigen directed immunoconjugate MLN2704 in patients with progressive metastatic castration-resistant prostate cancer
Matthew D. Galsky et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Recommendations on risk-based strategies for detection and characterization of antibodies against biotechnology products
Eugen Koren et al.
JOURNAL OF IMMUNOLOGICAL METHODS (2008)
Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology products
Gopi Shankar et al.
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS (2008)
Cetuximab-induced anaphylaxis and IgE specific for galactose-α-1,3-galactose
Christine H. Chung et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Cell killing by antibody-drug conjugates
Yelena V. Kovtun et al.
CANCER LETTERS (2007)
Immunotoxin treatment of cancer
Ira Pastan et al.
ANNUAL REVIEW OF MEDICINE (2007)
Adjuvant-enhanced antibody responses in the absence of toll-like receptor signaling
Amanda L. Gavin et al.
SCIENCE (2006)
Enhancing immunogenicity by limiting susceptibility to lysosomal proteolysis
Lelia Delamarre et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2006)
The analysis of doxorubicin resistance in human breast cancer cells using antibody microarrays
Laura Smith et al.
MOLECULAR CANCER THERAPEUTICS (2006)
Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing
HK Erickson et al.
CANCER RESEARCH (2006)
Lysosomal trafficking and cysteine protease metabolism confer target-specific cytotoxicity by peptide-linked anti-CD30-auristatin conjugates
MSK Sutherland et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
Antibody-drug conjugates designed to eradicate tumors with homogeneous and heterogeneous expression of the target antigen
YV Kovtun et al.
CANCER RESEARCH (2006)
Induction of autoimmunity by immunization with hapten-modified hen egg lysozyme in hen egg lysozyme-transgenic mice
HK Kang et al.
IMMUNOLOGY (2006)
An acid dissociation bridging ELISA for detection of antibodies directed against therapeutic proteins in the presence of antigen
A Patton et al.
JOURNAL OF IMMUNOLOGICAL METHODS (2005)
Safety and efficacy of gemtuzumab ozogamicin in pediatric patients with advanced CD33+ acute myeloid leukemia
RJ Arceci et al.
BLOOD (2005)
Cantuzumab mertansine, a maytansinoid immunoconjugate directed to the CanAg antigen: A phase I, pharmacokinetic, and biologic correlative study
AW Tolcher et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Contribution of conformational stability of hen lysozyme to induction of type 2 T-helper immune responses
T So et al.
IMMUNOLOGY (2001)
Share Paper
